Evidence map›Paper›PMID 19637286›Full record

ReviewHepatology (Baltimore, Md.)2009

Advances in pediatric nonalcoholic fatty liver disease.

Rohit Loomba, Claude B Sirlin, Jeffrey B Schwimmer, Joel E Lavine

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Hepatology (Baltimore, Md.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02116192 (Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents), which is not on this map. Cited by 107 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 3 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02116192 nacompletednot on this mapstarted 2014, after this paper: background citation

Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents

TypeinterventionalSponsorUniversity of Wisconsin, MadisonRan2014 to 2017Enrolled28ConditionsNon-alcoholic Fatty Liver DiseaseArmsExperimental: Low-fructose, reduced carbohydrate diet, General Healthy Diet
3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 3 syntheses or guidelines pooled it, 263 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Effects of Different Vegetable Oils on the Nonalcoholic Fatty Liver Disease in C57/BL Mice.Evidence-based complementary and alternative medicine : eCAM · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rohit LoombaDivision of Gastroenterology, Department of Medicine, University of California at San Diego and Rady Children's Hospital, San Diego, CA, USA.
Claude B Sirlin
Jeffrey B Schwimmer
Joel E Lavine
Rady Children's Hospital-San Diego · US

Funding

Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4M
The UCSD Digestive Diseases Research Development CenterR24DK080506 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS · 2008 to 2012
$2.7M
MR Imaging of Non-Alcoholic Fatty Liver DiseaseR01DK075128 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SIRLIN, CLAUDE B · 2006 to 2010
$2.4M
NIDDK NIH HHS R01 DK075128NIDDK NIH HHS R01DK075128NIDDK NIH HHS R24 DK080506NIDDK NIH HHS R24DK080506NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01DK61734
6 · The paper itself

Abstract

unlabelledNonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in children and adolescents in the United States. A two- to three-fold rise in the rates of obesity and overweight in children over the last two decades is probably responsible for the NAFLD epidemic. Emerging data suggest that children with nonalcoholic steatohepatitis (NASH) progress to cirrhosis, which may ultimately increase liver-related mortality. More worrisome is the recognition that cardiovascular risk and morbidity in children and adolescents are associated with fatty liver. Pediatric fatty liver disease often displays a histologic pattern distinct from that found in adults. Liver biopsy remains the gold standard for diagnosis of NASH. Noninvasive biomarkers are needed to identify individuals with progressive liver injury. Targeted therapies to improve liver histology and metabolic abnormalities associated with fatty liver are needed. Currently, randomized-controlled trials are underway in the pediatric population to define pharmacologic therapy for NAFLD.

conclusionPublic health awareness and intervention are needed to promote healthy diet, exercise, and lifestyle modifications to prevent and reduce the burden of disease in the community.

Indexed as

AdolescentBiomedical ResearchChildChild, PreschoolDietExerciseFatty LiverHumansLife StylePrevalenceUnited States

Identifiers

PMID19637286
PMCPMC2757471
OpenAlexW2005666028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.